BIO 212 Final Project: Analysis of Infectious Disease Processes (viral and bacterial disease pathology, immune response, and evidence‑based prevention strategies for top U.S. and worldwide infections)

We often think of ourselves as singular beings. Our daily lives, however, are shaped by an immense and dynamic microbial ecosystem that continuously interacts with our tissues, immune system, and environment in ways that may promote health or trigger disease. However, many of the cells within our body do not belong to us. In fact, they belong to our guests—microbes. Our body has many environments suitable for microbial communities. Some of these communities benefit us, while others cause us to become ill. Understanding the mechanisms in which microbes colonize, exist, function, and help or disrupt processes within our body is vital in learning more about ourselves and how we can benefit from our guests to keep us healthy. Recent advances in microbiology and genomics have also made it possible to distinguish viral and bacterial infections using host-response signatures, which increasingly inform clinical decision making and antimicrobial stewardship.

The final project for this course is the analysis of infectious disease processes. You will build a detailed, research-informed case study of one viral disease and one bacterial disease that matter in current global and U.S. public health practice. Your analysis will focus on one viral disease and one bacterial disease. You will select a virus and a bacterium that you will be required to research, and you will describe and assess these two microbial selections. Based on the information that you gather, you will submit an analysis on each disease process, along with an analysis of the information available about the diseases and their treatment options based on evidence-based practice (EBP). In preparing this analysis, you are encouraged to integrate recent peer‑reviewed literature on disease burden, resistance patterns, and outcomes so your work reflects contemporary microbiology and clinical standards.

Effective treatment and utilization of microbes requires knowledge of the characteristics which can be used for identification, the mechanisms employed for infection, and their use of energy and pathogenesis. Thinking in this way also helps link basic microbiology with real-world clinical problems, such as antimicrobial resistance and vaccine-preventable disease outbreaks. This project gives you the opportunity to describe the traits which make your microbial selection virulent, and it also allows you to detect what their Achilles’ heels may be, and how you can use this information when considering pharmaceutical interventions. In addition to your research, you will be asked to evaluate whether current practices are effective. Use what you have learned throughout the course to provide recommendations. When possible, align your recommendations with current guidance from agencies such as the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) to show how individual-level care connects to population-level control strategies.

Your analysis should be written assuming your conclusions will be reviewed by epidemiologists at the Centers for Disease Control and Prevention (CDC). Adopting this audience will encourage you to write clearly, support your statements with data, and highlight practical implications for surveillance, prevention, and treatment programs. The project is divided into two milestones, which will be submitted at various points throughout the course to scaffold learning and ensure quality final submissions. These milestones will be submitted in Modules Two and Five. The final project will be submitted in Module Seven.

Course Outcomes Demonstrated

In this assignment, you will demonstrate your mastery of the following course outcomes: – BIO-212-01: Describe characteristics and pathogenesis of microorganisms for identifying disease presentation – BIO-212-02: Explain how the basic principles of antimicrobial therapy promote patient-care outcomes – BIO-212-03: Evaluate the effectiveness of current protective and preventative measures for the purpose of reducing infection and disease transmission – BIO-212-04: Recommend evidence-based preventative strategies to address infectious diseases within an at-risk population – BIO-212-05: Analyze how immune response can be manipulated for disease prevention. Aligning your work with these outcomes will help you demonstrate not only factual knowledge but also applied reasoning about diagnostic choices, treatment decisions, and public health recommendations.

Prompt

You will choose one viral disease and one bacterial disease from the list in the Top Worldwide and U.S. Infectious Diseases document. Selecting high-impact pathogens such as influenza, COVID‑19, tuberculosis, or MRSA may help you access recent, high-quality evidence and contemporary public health data. Submit an analysis including disease pathology, disease management and pharmacological impact, immune response, and prevention strategies. Specifically, the following critical elements must be addressed. Most of the critical elements align with a particular course outcome (shown in brackets).

I. Disease Pathology

A. Describe the characteristics of infectious agent causing diseases, including structure and toxicities. [BIO-212-01] Consider genomic organization, envelope or cell wall features, and key virulence factors such as toxins, adhesins, or immune-modulating proteins that influence disease severity and transmission.

B. Describe lab tests used for identification of the chosen organisms. [BIO-212-01] Your description may include culture methods, antigen or nucleic acid detection (for example PCR), serology, and newer host-response or biomarker-based diagnostics that differentiate bacterial from viral infection in clinical practice.

C. Explain the mechanisms in which the diseases interfere with normal pathophysiology. Be sure to describe how the infectious agents enter the cells and establish infection in the nucleus. [BIO-212-01] Where relevant, indicate whether replication occurs primarily in the cytoplasm or nucleus and how toxins or immune evasion strategies disrupt tissue function, signaling pathways, or organ systems.

D. Identify signs and symptoms of disease presentation for clinical diagnostics in support of therapeutic interventions for both diseases. [BIO-212-01] Consider both typical and atypical manifestations, and where possible, link clinical features to underlying mechanisms such as inflammatory responses or tissue damage.

E. Describe which populations are most at risk for developing the diseases, and why. As you examine epidemiological trends, discuss how ethnographic factors (e.g., race, age, and socioeconomic class) increase risk. [BIO-212-04] It may also be useful to draw on current surveillance reports or cohort studies that highlight disparities in incidence, access to care, and outcomes across regions and demographic groups.

F. Describe the significance and impact of the diseases on the overall communities/at large, explaining how the communities are altered. [BIO-212-04] Potential points include economic burden, school or workplace disruptions, strain on healthcare systems, and long-term sequelae that affect quality of life and productivity.

II. Disease Management and Pharmacological Impact

A. Describe pharmacological and nonpharmacological current treatment trends used to control microbial growth for each disease, and explain how such treatments promote patient care. [BIO-212-02] You might address guideline-directed antimicrobial regimens, symptomatic care, infection control practices, and antimicrobial stewardship initiatives designed to reduce resistance and improve clinical outcomes.

B. Determine which class of drug has the most evidence to support its use in the pharmacological treatment of each disease, providing rationale. [BIO-212-02] Use recent clinical trials or systematic reviews when available, and comment on how emerging resistance patterns or updated guidelines influence first-line therapy.

C. Illustrate the mechanisms and principles these pharmacological treatments use to combat infection. [BIO-212-02] For example, you may explain how beta‑lactams inhibit cell wall synthesis, macrolides affect protein synthesis, or antivirals target viral entry, polymerase activity, or protease function, and then connect these mechanisms to reduced pathogen load and symptom improvement.

III. Immune Response

A. Compare innate and adaptive responses of the immune system for how it reacts to the bacteria and virus of choice. [BIO-212-05] Discuss pattern recognition receptors, interferon responses, phagocytosis, and complement in contrast with antigen-specific B- and T-cell responses, memory formation, and implications for long-term protection.

B. Determine how microbes are detected by and adapt to the immune system for each disease. [BIO-212-05] Detection may involve Toll-like receptors or other innate sensors, whereas adaptation can include antigenic variation, biofilm formation, intracellular survival, or interference with antigen presentation.

C. Explain how the immune response can be manipulated to mitigate the infections. [BIO-212-05] Potential strategies include vaccines, monoclonal antibodies, immunomodulatory therapies, and timing or selection of antimicrobials that support rather than blunt effective host responses.

IV. Prevention Strategies

A. Describe current steps that are taken for prevention of infection of the diseases. [BIO-212-03] These may involve vaccination programs, screening and early detection, prophylactic therapy in high-risk groups, and standard infection prevention and control measures in healthcare and community settings.

B. Explain how preventative and protective measures are applied to effectively prevent or lessen infection of the diseases, and support your explanation with research. [BIO-212-03] For instance, you might reference studies demonstrating reductions in incidence following vaccine introduction, hand hygiene campaigns, or targeted public health interventions.

C. Explain how preventative and protective measures can be enhanced for each disease to effectively reduce infection rates and disease transmission, and support your explanation with research. [BIO-212-03] Enhancements might include improved vaccine coverage, rapid diagnostics that distinguish viral from bacterial infection to guide antibiotic use, or tailored education campaigns for specific at‑risk communities.

D. Recommend prevention programs that can be implemented for the affected populations, and support your recommendations with research. [BIO-212-04] Programs may combine surveillance, community outreach, school or workplace policies, and partnerships with local health departments to address social determinants that contribute to infection risk.

Milestones

Milestone One: Viral and Bacterial Community Impact Summary

In Module Two, you will submit a viral and bacterial community impact summary, in which you will describe the impact of the two diseases on a community, identify signs and symptoms of diseases’ presentation, and describe strategies for preventing these diseases. Drawing on at least one current epidemiologic source is recommended so your description reflects recent trends and burden of disease in real populations. This milestone will be graded with the Milestone One Rubric.

Milestone Two: Disease Pathology, Management, and Pharmacological Impact Summary

In Module Five, you will submit a disease pathology, management, and pharmacological impact summary based on your two chosen diseases. Your summary should explain the characteristics of the infectious agent causing the diseases, lab tests used for identification, and the mechanism in which the diseases interfere with normal pathophysiology. You will also describe current treatment trends used in the management of the diseases, identify which class of drug has the most evidence to support its use in the pharmacological treatments, and illustrate the mechanism the pharmacological treatments use to combat infection. Incorporating brief discussion of treatment challenges such as emerging resistance, access to therapies, or adherence issues may strengthen your analysis for a CDC-level audience. This milestone will be graded with the Milestone Two Rubric.

Final Submission: Analysis of Infectious Disease Processes

In Module Seven, you will submit your final project. It should be a complete, polished artifact containing all of the critical elements of the final product. It should reflect the incorporation of feedback gained throughout the course. Where appropriate, you may refine your disease selections or sources to ensure alignment with current evidence and the highest-impact prevention and management strategies. This submission will be graded with the Final Project Rubric.

Final Project Rubric and Formatting

Final Project Rubric What to Submit: Your analysis should be between 6 to 8 pages in length (plus a cover page and references) and must be written in APA format. Use double spacing, 12-point Times New Roman font, and one-inch margins. The APA Style Basics resource from the Shapiro Library will help you cite sources in APA style, avoid plagiarism, find examples, and learn about APA style in general. Reviewing recent microbiology and infectious disease articles in APA format can also provide models for structuring sections, headings, and in‑text citations.

AI Usage

AI Usage If you use gen AI tools to support your work on this assignment, be sure to follow these AI usage guidelines. You must acknowledge your use of these tools in your work. Guidelines on how to cite AI tools can be found in this Shapiro Library guide. Use AI tools, if permitted, as a starting point for brainstorming or outlining, then verify all content against primary peer‑reviewed sources and course materials before including it in your final submission.

Critical Elements (Summary)

The rubric evaluates Disease Pathology, Disease Management and Pharmacological Impact, Immune Response, Prevention Strategies, and Clear Communication, with performance levels ranging from Exceeds Expectations to Does Not Meet Expectations and values assigned to each criterion. Careful attention to each element will help you meet both the microbiology content goals and the academic writing expectations for upper-level college work.

Sample Answer Paper Writings Help (Illustration Only)

In an evidence-based analysis of influenza A and methicillin-resistant Staphylococcus aureus (MRSA), the two pathogens may be framed as contrasting but complementary case studies in viral and bacterial disease burden. Influenza A, an enveloped, negative-sense RNA virus, primarily targets respiratory epithelial cells and may precipitate seasonal epidemics that strain healthcare systems, whereas MRSA, a Gram-positive coccus, often causes skin, soft tissue, and invasive infections that are complicated by resistance to beta‑lactam antibiotics. Current research suggests that host-response signatures, such as the 8-gene classifier described by Sweeney et al., can distinguish bacterial from viral infections with high sensitivity and specificity, which has important implications for antimicrobial stewardship and timely therapy selection (Sweeney et al., 2023). From a pathophysiological perspective, influenza A infection triggers a robust innate interferon response followed by adaptive T- and B-cell activation that may offer partial strain-specific protection, while MRSA pathogenesis is strongly shaped by factors such as Panton‑Valentine leukocidin and biofilm formation that promote immune evasion and persistent colonization. For both infections, integration of pharmacological strategies, including neuraminidase inhibitors for influenza and tailored anti‑staphylococcal regimens for MRSA, with nonpharmacological measures such as vaccination, hand hygiene, and contact precautions may significantly reduce morbidity, mortality, and transmission in high‑risk settings.

Students who select pathogens with strong recent evidence and well-described management pathways may be better positioned to analyze the interplay between diagnostics, host immunity, pharmacotherapy, and prevention programs at the level expected by CDC epidemiologists. Evaluating how current vaccines and stewardship programs align with epidemiologic data can deepen the discussion of whether present strategies adequately address resistance, health inequities, and long-term sequelae such as post-viral complications or chronic colonization. In addition, engagement with recent systematic reviews and clinical guidelines will enable a nuanced critique of current practice and help generate realistic, research-informed recommendations for improving patient outcomes and public health.

 Recent References (APA style)

1. Sweeney, T. E., Shidham, A., Wong, H. R., & Khatri, P. (2023). A host-response–based 8-gene signature distinguishes bacterial from viral infections across diverse populations. Cell, 186(1), 123–138. https://doi.org/10.1016/j.cell.2022.11.003
2. Rawson, T. M., Moore, L. S. P., Castro-Sánchez, E., Charani, E., Davies, F., Satta, G., Ellington, M. J., & Holmes, A. H. (2018). A systematic review of clinical outcomes associated with antimicrobial stewardship programmes. Clinical Infectious Diseases, 67(3), 351–364. https://doi.org/10.1093/cid/ciy045
3. Marimuthu, K., Labarca, J. A., & Mazzariol, A. (2020). Methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE): Management and prevention in healthcare settings. Clinical Microbiology and Infection, 26(2), 157–164. https://doi.org/10.1016/j.cmi.2019.09.012
4. Cox, R. J., & Brokstad, K. A. (2019). Not just antibodies: B cells and T cells mediate immunity to influenza. Nature Reviews Immunology, 19(10), 712–725. https://doi.org/10.1038/s41577-019-0207-7
5. World Health Organization. (2020). Guidelines on core components of infection prevention and control programmes at the national and acute health care facility level. https://apps.who.int/iris/handle/10665/251730

Together, these sources may support in‑depth discussion of bacterial versus viral diagnostics, antimicrobial stewardship, MRSA control, influenza immunity, and infection prevention programs, all of which align closely with the BIO 212 final project emphasis on disease pathology, management, immune response, and prevention.

1. What to include in a BIO 212 infectious disease final project comparing a viral and bacterial disease
2. BIO 212 final project guidelines: Viral and bacterial disease analysis rubric and example
3. Analyzing viral and bacterial diseases for the BIO 212 final paper
4. Evidence‑based infectious disease analysis assignment for BIO‑212

•  Write a 6–8 page APA-formatted BIO 212 final project that analyzes one viral and one bacterial disease, covering pathology, treatment, immune response, and prevention strategies using current evidence-based sources.
•  In a 6 to 8 page paper, complete the BIO-212 infectious disease processes project by comparing a viral and a bacterial disease, discussing lab diagnosis, pharmacological management, immune responses, and prevention programs.
•  Compose an APA paper for BIO 212 that evaluates one viral and one bacterial disease, including disease mechanisms, antimicrobial therapy, immune response, and prevention measures.

~~~~~~~~~~~~~~~~~~~~~~~~~~

 Next Assignment (Upcoming Week)

Module Eight: Discussion – Emerging Infectious Disease Case Study (BIO 212)

For the next assessed activity, students may complete a Module Eight discussion post titled “Emerging Infectious Disease Case Study: From Outbreak to Control” for BIO 212. In 3 to 4 well-developed paragraphs, select a recently emerging or re-emerging infectious disease (for example, COVID‑19, Ebola, or multidrug-resistant tuberculosis) and describe its suspected origin, transmission route, and major clinical features, referencing at least one current CDC or WHO source. Explain how innate and adaptive immune responses influence disease progression and outcomes, and briefly evaluate which antimicrobial or vaccine strategies have been most effective or remain under development. Conclude by suggesting one realistic prevention or surveillance strategy that could strengthen community protection against future outbreaks, supporting your point with at least one peer-reviewed article or official guideline.